RHJA
NXGN

Rice Hall James & Associates’s NextGen Healthcare, Inc. Common Stock NXGN Stock Holding History

Rice Hall James & Associates’s Portfolio NXGN Stock Details NXGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-385,274
Closed -$9.14M – 269
2023
Q3 		$9.14M Sell
385,274
-3,495
-0.9% -$65.8K 0.58% 48
2023
Q2 		$6.31M Sell
388,769
-22,378
-5% -$371K 0.36% 70
2023
Q1 		$7.16M Sell
411,147
-6,565
-2% -$118K 0.41% 58
2022
Q4 		$7.84M Buy
417,712
+84,470
+25% +$1.63M 0.45% 57
2022
Q3 		$5.9M Buy
+333,242
New +$5.78M 0.34% 69
2016
Q4 		– Sell
-686,678
Closed -$7.77M – 311
2016
Q3 		$7.77M Sell
686,678
-3,615
-0.5% -$43.4K 0.41% 85
2016
Q2 		$8.22M Sell
690,293
-8,993
-1% -$121K 0.47% 79
2016
Q1 		$10.7M Sell
699,286
-57
-0% -$865 0.62% 70
2015
Q4 		$11.3M Buy
+699,343
New +$10.2M 0.64% 65

Other funds holding NXGN

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rice Hall James & Associates's NXGN Position: Q4 2023 in Review

Rice Hall James & Associates sold out of NextGen Healthcare, Inc. Common Stock (NXGN) in Q4 2023, closing a stake of 385,274 shares — an estimated $9.14M sold.

Rice Hall James & Associates first reported a position in NXGN in Q4 2015 and held it in 9 quarters. The position peaked at $11.3M in Q4 2015. 1 fund tracked by Wall St. Rank holds NXGN as of Q4 2023.

  • Rice Hall James & Associates reported no remaining NextGen Healthcare, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Rice Hall James & Associates sold 385,274 NextGen Healthcare, Inc. Common Stock shares in Q4 2023, an estimated $9.14M.
  • Rice Hall James & Associates first reported a position in NextGen Healthcare, Inc. Common Stock in Q4 2015 and held it in 9 quarters.
  • Rice Hall James & Associates's NextGen Healthcare, Inc. Common Stock position peaked at $11.3M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held NextGen Healthcare, Inc. Common Stock as of Q4 2023.

Based on Rice Hall James & Associates's 13F filing for Q4 2023, filed 9 Feb 2024.